Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

NCT05010772 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Decitabine and Cedazuridine
DRUG: Enasidenib
DRUG: Gilteritinib
DRUG: Ivosidenib
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]